Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...

New England Journal of Medicine Publishes eNRGy Trial Evaluating Zenocutuzumab-zbco (BIZENGRI®) in NRG1+ cancer ...

Taking place on February 14-16, 2025, in Washington, the American College of Cardiology (ACC) Advancing the Cardiovascular Care of the Oncology Patient conference is an interdisciplinary and ...

India's first heart failure registry reveals younger patients, high mortality rates, and varying causes of heart failure.

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

In December, YNHH integrated the newly FDA-approved Medtronic VitalFlow ECMO System and first used it to transfer a patient ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

A couple who had to make the difficult decision to tell doctors to halt CPR on their newborn child are opening up about ...

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...